MAPS & PTSD Luminaries to Host Press Conference Following FDA’s PTSD Treatment Review
Panel Experts include: Bessel van der Kolk, M.D., Dave Rabin M.D., Ph.D., Darron Smith, Ph.D., PA-C, DFAAPA, Michael Mithoefer, M.D. and Betty Aldworth
WASHINGTON, D.C. (September 6, 2024) – Today, The Multidisciplinary Association for Psychedelic Studies (MAPS) will host a press conference following the US Food and Drug Administration (FDA) public meeting on potential new treatments for PTSD, including psychedelic-assisted therapies. This press conference will address key points covered in the FDA meeting and discuss potential next steps in the field of psychedelic research and therapy, and offer the media an opportunity to gain expert insights and commentary on the FDA’s discussions regarding innovative PTSD treatments, particularly focusing on psychedelic-assisted therapies.
What: MAPS Press Conference on FDA’s PTSD Treatment Review
Who:
Bessel van der Kolk, M.D., psychiatrist, author of The New York Times best-seller, The Body Keeps the Score, and educator, who has been the leading researcher in the area of post-traumatic stress since the 1970s.
Dave Rabin M.D., Ph.D., board-certified psychiatrist, neuroscientist, entrepreneur, and inventor who has studied resilience and the impact of chronic stress on our lives for more than 15 years.
Darron Smith, Ph.D., PA-C, DFAAPA, US Army veteran and board-certified physician associate whose latest research and practice intersect the study of applied neuroscience (neurofeedback therapy) and psychedelic research (MDMA, Ketamine, Psilocybin) with victims of childhood trauma.
Michael Mithoefer, M.D., psychiatrist, pioneer in MDMA-assisted psychotherapy research, and Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation (MAPS PBC).
Betty Aldworth, Communications Director & Post-Prohibition Strategy for MAPS
When:
Friday, September 6, 2024
4:30 p.m. EST
How to Attend: Please join via the Zoom link below.
https://us02web.zoom.us/webinar/register/WN_iXSUlg7-SxaQhy913HXwyg#/registration
About MAPS
Founded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS previously sponsored the most advanced psychedelic-assisted therapy research in the world and continues to support psychedelic and marijuana research with a focus on the people and places most impacted by trauma. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and The Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance psychedelic research, change drug policy, and shape culture.
